Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1983 1
1984 2
1985 1
1986 5
1987 8
1988 3
1989 3
1990 4
1991 3
1992 20
1993 18
1994 50
1995 16
1996 9
1997 18
1998 14
1999 14
2000 17
2001 13
2002 13
2003 20
2004 19
2005 11
2006 19
2007 17
2008 10
2009 9
2010 9
2011 9
2012 14
2013 17
2014 15
2015 18
2016 15
2017 6
2018 9
2019 8
2020 10
2021 11
2022 7
2023 1
Text availability
Article attribute
Article type
Publication date

Search Results

463 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Usefulness of Arbekacin.
Lee JH, Lee CS. Lee JH, et al. Infect Chemother. 2016 Mar;48(1):1-11. doi: 10.3947/ic.2016.48.1.1. Epub 2016 Mar 31. Infect Chemother. 2016. PMID: 27104010 Free PMC article. Review.
Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). ...The microbiologic efficacy rate ranged from 46.2% to 83%. In comparative studies between arbekacin and glycopeptides, arbekacin was similar to ot …
Arbekacin is a broad-spectrum aminoglycoside used to treat methicillin-resistant Staphylococcus aureus (MRSA). ...The microbiologic e …
Arbekacin.
Kobayashi Y, Uchida H, Kawakami Y. Kobayashi Y, et al. Int J Antimicrob Agents. 1995 Jul;5(4):227-30. doi: 10.1016/0924-8579(95)00014-y. Int J Antimicrob Agents. 1995. PMID: 18611673 No abstract available.
Synthesis of 5-deoxy-5-epifluoro derivatives of arbekacin, amikacin, and 1-N-[(S)-4-amino-2-hydroxybutanoyl]tobramycin (study on structure--toxicity relationships).
Shitara T, Umemura E, Tsuchiya T, Matsuno T. Shitara T, et al. Carbohydr Res. 1995 Oct 16;276(1):75-89. doi: 10.1016/0008-6215(95)00123-b. Carbohydr Res. 1995. PMID: 8536259
The acute toxicities of these three 5-deoxy-5-epifluoro compounds showed values almost identical or similar to those for arbekacin (ABK) and amikacin (15), making a sharp contrast with the toxicities of the corresponding 5-deoxy-5-fluoro derivatives. ...
The acute toxicities of these three 5-deoxy-5-epifluoro compounds showed values almost identical or similar to those for arbekacin (A …
Synthesis and antibacterial activity of 5-deoxy-5-episubstituted arbekacin derivatives.
Hiraiwa Y, Usui T, Akiyama Y, Maebashi K, Minowa N, Ikeda D. Hiraiwa Y, et al. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3540-3. doi: 10.1016/j.bmcl.2007.04.065. Epub 2007 Apr 25. Bioorg Med Chem Lett. 2007. PMID: 17502146
5-Deoxy-5-episubstituted arbekacin derivatives have been designed and efficiently synthesized. ...The 6'-N-methyl derivative of the 5-epi arbekacin was effective against Pseudomonas aeruginosa expressing the aminoglycoside-modifying enzyme AAC(6')....
5-Deoxy-5-episubstituted arbekacin derivatives have been designed and efficiently synthesized. ...The 6'-N-methyl derivative of the 5 …
[MRSA].
Hanaki H. Hanaki H. Nihon Rinsho. 2001 Nov;59 Suppl 7:214-22. Nihon Rinsho. 2001. PMID: 11808124 Review. Japanese. No abstract available.
Kanamycin and its derivative, arbekacin: significance and impact.
Hotta K, Kondo S. Hotta K, et al. J Antibiot (Tokyo). 2018 Mar;71(4):417-424. doi: 10.1038/s41429-017-0017-8. Epub 2018 Feb 5. J Antibiot (Tokyo). 2018. PMID: 29402999 Review.
On the occasion of the 60th anniversary of the discovery (1957) of kanamycin (KM), a series of research achievements on KM and its semisynthetic derivative Arbekacin (ABK) are outlined. KM was first used clinically in 1958 and was appreciated for its remarkable curing effe …
On the occasion of the 60th anniversary of the discovery (1957) of kanamycin (KM), a series of research achievements on KM and its semisynth …
[Molecular therapies for Duchenne muscular dystrophy].
Takeshima Y. Takeshima Y. No To Hattatsu. 2016 Jul;48(4):241-6. No To Hattatsu. 2016. PMID: 30010301 Review. Japanese.
The clinical effectiveness of gentamicxin and PTC124 has been reported. We have demonstrated the effectiveness of arbekacin-mediated read-through in vitro. We have already begun an investigator initiated clinical trial of nonsense mutation read-through therapy using arb …
The clinical effectiveness of gentamicxin and PTC124 has been reported. We have demonstrated the effectiveness of arbekacin-mediated …
[Nonsense readthrough therapy for Duchenne muscular dystrophy].
Takeshima Y. Takeshima Y. Rinsho Shinkeigaku. 2014;54(12):1074-6. doi: 10.5692/clinicalneurol.54.1074. Rinsho Shinkeigaku. 2014. PMID: 25672712 Review. Japanese.
Clinical effectiveness of gentamicin and PTC124 have been suggested. We have demonstrated that arbekacin-mediated readthrough can substantially ameliorate muscular dystrophy. We already have begun the clinical trial of the nonsense mutation readthrough therapy using arb …
Clinical effectiveness of gentamicin and PTC124 have been suggested. We have demonstrated that arbekacin-mediated readthrough can sub …
In vitro activity of arbekacin against multidrug-resistant gram-negative bacilli.
Albano M, Fleischmann WA, Greenwood-Quaintance KE, Patel R. Albano M, et al. J Microbiol Immunol Infect. 2021 Dec;54(6):1118-1121. doi: 10.1016/j.jmii.2020.08.018. Epub 2020 Sep 9. J Microbiol Immunol Infect. 2021. PMID: 32962921 Free article.
BACKGROUND: Arbekacin is a broad-spectrum aminoglycoside with activity against some Gram-positive and Gram-negative bacteria. METHODS: Arbekacin minimum inhibitory concentration (MIC) values were determined for 296 drug-resistant Gram-negative bacilli, and compared …
BACKGROUND: Arbekacin is a broad-spectrum aminoglycoside with activity against some Gram-positive and Gram-negative bacteria. METHODS …
The efficacy and safety of arbekacin and vancomycin for the treatment in skin and soft tissue MRSA infection: preliminary study.
Hwang JH, Lee JH, Moon MK, Kim JS, Won KS, Lee CS. Hwang JH, et al. Infect Chemother. 2013 Mar;45(1):62-8. doi: 10.3947/ic.2013.45.1.62. Epub 2013 Mar 29. Infect Chemother. 2013. PMID: 24265951 Free PMC article.
We studied the clinical and bacteriological efficacy and safety of arbekacin compared to vancomycin in the treatment of infections caused by MRSA. ...The complication rate was significantly higher in the vancomycin group [29/59(49.2%), 95% CI 35.9 to 62.5%] than arbekac …
We studied the clinical and bacteriological efficacy and safety of arbekacin compared to vancomycin in the treatment of infections ca …
463 results